Overview

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Status:
Completed
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
AB Science
Treatments:
Docetaxel
Prednisone